Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Market Closed - London S.E.
Other stock markets
 16:35:14 02/05/2024 BST 		5-day change 1st Jan Change
310 GBX +3.33% Intraday chart for HUTCHMED (China) Limited +6.90% +9.54%
04-26 EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug MT
04-26 Hutchmed notes CHMP's positive opinion for fruiquintinib approval AN

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • With an enterprise value anticipated at 3.59 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HUTCHMED (CHINA) LIMITED Stock HUTCHMED (China) Limited
+9.54% 3.2B
C+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 699B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.77% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 154B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. HCM Stock
  4. Ratings HUTCHMED (China) Limited